-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B
-
-
-
-
-
-
-
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
-
1,198,886 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

